An action plan for pan-European defence against new SARS-CoV-2 variants
COVID-19 cases are very high across Europe. Current measures are not reducing virus
spread sufficiently, and new severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
spread sufficiently, and new severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older
Methods| This population-based study used the French National Health Data System linked
to the national COVID-19 vaccination database. Eligible participants were all persons …
to the national COVID-19 vaccination database. Eligible participants were all persons …
Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and …
Background Although most children and adolescents have had a previous SARS-CoV-2
infection and many continue to receive COVID-19 vaccinations, studies of the effectiveness …
infection and many continue to receive COVID-19 vaccinations, studies of the effectiveness …
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
M Levine-Tiefenbrun, I Yelin, H Alapi, R Katz… - Nature medicine, 2021 - nature.com
The effectiveness of the coronavirus disease 2019 (COVID-19) BNT162b2 vaccine in
preventing disease and reducing viral loads of breakthrough infections (BTIs) has been …
preventing disease and reducing viral loads of breakthrough infections (BTIs) has been …
[HTML][HTML] The SARS-CoV-2 B. 1.351 lineage (VOC β) is outgrowing the B. 1.1. 7 lineage (VOC α) in some French regions in April 2021
B Roquebert, S Trombert-Paolantoni… - …, 2021 - eurosurveillance.org
To assess SARS-CoV-2 variants spread, we analysed 36,590 variant-specific reverse-
transcription-PCR tests performed on samples from 12 April–7 May 2021 in France. In this …
transcription-PCR tests performed on samples from 12 April–7 May 2021 in France. In this …
Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and-experienced subjects: impact of …
S Desmecht, A Tashkeev, M El Moussaoui… - Frontiers in …, 2022 - frontiersin.org
Background Understanding and measuring the individual level of immune protection and its
persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory …
persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory …
[HTML][HTML] Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective …
Background: BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have
been rapidly rolled out in the UK. We determined the factors associated with vaccine …
been rapidly rolled out in the UK. We determined the factors associated with vaccine …
Spread of a variant SARS-CoV-2 in long-term care facilities in England
M Krutikov, A Hayward… - New England Journal of …, 2021 - Mass Medical Soc
Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …
Sensitivity of the SARS-CoV-2 BA. 2.86 variant to prevailing neutralising antibody responses
DJ Sheward, Y Yang, M Westerberg, S Öling… - The Lancet Infectious …, 2023 - thelancet.com
SARS-CoV-2 lineages, a substantially mutated sublineage of BA. 2 has recently emerged.
Designated BA. 2.86, 1 the geographic origin of this sublineage is currently unclear and, as …
Designated BA. 2.86, 1 the geographic origin of this sublineage is currently unclear and, as …
The BNT162b2 vaccine is associated with lower new COVID‐19 cases in nursing home residents and staff
M Domi, M Leitson, D Gifford, A Nicolaou… - Journal of the …, 2021 - Wiley Online Library
Abstract Background/Objectives The effectiveness of the BNT162b2 vaccine on preventing
the spread of COVID‐19 and deaths in nursing homes (NH) is unknown. Design We used …
the spread of COVID‐19 and deaths in nursing homes (NH) is unknown. Design We used …